The benefits of deep-tech Corporate Venturing (CV) are compelling. That’s why chief innovation officers must tackle not-invented-here syndrome, risk aversion, and top-down cultures to successfully collaborate with deep-tech startups. To address NIH syndrome, a shared mandate between R&D and CV can help overcome internal biases and siloed decision-making while encouraging choices that are best for the organization as a whole. Deep tech is often associated with high risk, which can cause corporate leaders to block efforts to adopt and catalyze external innovation. To appropriately evaluate risk, senior managers should evaluate the risk levels their peers are willing to take on and choose mechanisms to match. Many times, we at P&C also recommend creating a sandbox—basically a minimum proof of concept environment, as a way of addressing risk. Furthermore, if your company’s top-down culture is getting in the way, you can enlist internal advocates or turn to outside experts to help make a convincing case. Contact us to learn more about how we help our clients effectively harness the value of deep-tech venturing.

Further Reading

Research & Insights

Navigating the Aftermath: Lessons from the Silicon Valley Bank Collapse for the Global Startup Ecosystem

Further Reading
Research & Insights

10 Practical Tips for Employees to Safeguard Their Trade Secrets During COVID-19

Further Reading
Research & Insights

Manage the Suppliers That Could Harm Your Brand

Further Reading

Let's Get to Work

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
By using this website, you agree to the use of cookies as described in our Privacy Policy